Eupraxia Pharmaceuticals Announces Positive Data From Fifth Cohort Of RESOLVE Phase 1B/2A Trial Of EP-104GI For Treatment Of Eosinophilic Esophagitis
One of three patients in Cohort 5 achieved complete histological remission at 12 weeks. <li /> Consistent improve ...
Joplin Globe6d
Castle Biosciences Surpasses 25,000 Test Reports Delivered for its TissueCypher® Barrett’s Esophagus Test
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced a significant milestone for the Company’s TissueCypher Barrett’s ...